Barclays’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-88,521
| Closed | -$1.39M | – | 5409 |
|
|
2024
Q1 | $1.39M | Sell |
88,521
-76,592
| -46% | -$1.18M | ﹤0.01% | 2866 |
|
|
2023
Q4 | $2.66M | Buy |
165,113
+51,072
| +45% | +$651K | ﹤0.01% | 2679 |
|
|
2023
Q3 | $1.45M | Sell |
114,041
-27,554
| -19% | -$380K | ﹤0.01% | 2091 |
|
|
2023
Q2 | $1.99M | Buy |
141,595
+16,026
| +13% | +$229K | ﹤0.01% | 1887 |
|
|
2023
Q1 | $1.94M | Sell |
125,569
-42,770
| -25% | -$714K | ﹤0.01% | 2224 |
|
|
2022
Q4 | $2.76M | Buy |
168,339
+12,109
| +8% | +$197K | ﹤0.01% | 2027 |
|
|
2022
Q3 | $2.89M | Buy |
156,230
+114,082
| +271% | +$1.79M | ﹤0.01% | 1504 |
|
|
2022
Q2 | $554K | Sell |
42,148
-138,226
| -77% | -$1.53M | ﹤0.01% | 2790 |
|
|
2022
Q1 | $1.67M | Buy |
180,374
+40,091
| +29% | +$341K | ﹤0.01% | 2009 |
|
|
2021
Q4 | $1.37M | Buy |
140,283
+76,704
| +121% | +$1.44M | ﹤0.01% | 2617 |
|
|
2021
Q3 | $2.16M | Buy |
63,579
+33,186
| +109% | +$1.06M | ﹤0.01% | 2287 |
|
|
2021
Q2 | $1.11M | Sell |
30,393
-59,974
| -66% | -$2.32M | ﹤0.01% | 2590 |
|
|
2021
Q1 | $4.05M | Buy |
90,367
+37,057
| +70% | +$1.73M | ﹤0.01% | 1700 |
|
|
2020
Q4 | $3.04M | Buy |
53,310
+32,563
| +157% | +$1.93M | ﹤0.01% | 1910 |
|
|
2020
Q3 | $1.06M | Sell |
20,747
-22,053
| -52% | -$1.08M | ﹤0.01% | 2633 |
|
|
2020
Q2 | $2.56M | Sell |
42,800
-15,120
| -26% | -$809K | ﹤0.01% | 1882 |
|
|
2020
Q1 | $2.38M | Buy |
57,920
+26,512
| +84% | +$1.47M | ﹤0.01% | 2133 |
|
|
2019
Q4 | $1.96M | Sell |
31,408
-2,140
| -6% | -$102K | ﹤0.01% | 3022 |
|
|
2019
Q3 | $1.14M | Buy |
33,548
+23,967
| +250% | +$709K | ﹤0.01% | 3537 |
|
|
2019
Q2 | $216K | Sell |
9,581
-482
| -5% | -$11.3K | ﹤0.01% | 5036 |
|
|
2019
Q1 | $234K | Sell |
10,063
-3,845
| -28% | -$101K | ﹤0.01% | 4706 |
|
|
2018
Q4 | $292K | Buy |
13,908
+9,073
| +188% | +$223K | ﹤0.01% | 4306 |
|
|
2018
Q3 | $188K | Buy |
4,835
+3,706
| +328% | +$137K | ﹤0.01% | 5049 |
|
|
2018
Q2 | $44K | Sell |
1,129
-3,116
| -73% | -$91.7K | ﹤0.01% | 5713 |
|
|
2018
Q1 | $86K | Buy |
4,245
+2,937
| +225% | +$74.4K | ﹤0.01% | 5490 |
|
|
2017
Q4 | $30K | Sell |
1,308
-23,692
| -95% | -$464K | ﹤0.01% | 6077 |
|
|
2017
Q3 | $475K | Buy |
+25,000
| New | +$458K | ﹤0.01% | 3683 |
|
Other funds holding DCPH
Barclays's DCPH Position: Q2 2024 in Review
Barclays sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 88,521 shares — an estimated $1.39M sold.
Barclays first reported a position in DCPH in Q3 2017 and held it in 27 quarters. The position peaked at $4.05M in Q1 2021. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Barclays reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Barclays sold 88,521 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $1.39M.
- Barclays first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 27 quarters.
- Barclays's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $4.05M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.